Racura Oncology LtdASX: RAC

Appendix 3Y - Dr Daniel Tillett

Sep 22, 2026 at 6:39 PM EDT · Issued by Racura Oncology Ltd via ASX

Filed with ASX · Sep 22, 2026 at 6:39 PM EDT

On 6ix: 6ix.com/news/appendix-3y-dr-daniel-tillett-1

Racura Oncology Ltd | ABN 61 149 318 749 | L36 1 Macquarie Place Sydney NSW 2000 Australia +61 2 8051 3043 | info@racuraoncology.com | www.racuraoncology.com 1 ASX Announcement Appendix 3Y Change of Director’s Interest Notice Dr Daniel Tillett 23 September 2026 This notice reflects the on-market...

View Attachment

6ix hasn’t read this filing yet.

Racura Oncology Ltd on 6ix

Story so far

Dr Daniel Tillett appointed CEO of Race OncologyNov 22, 2023

Earlier from Racura Oncology

RC220 MYC-silencing data to be presented FCS 26 conferenceSep 7
Racura Oncology Adelaide Investor BriefingSep 3
Notification regarding unquoted securities - RACAug 31
CPACS Trial Opens for RC220 Patient Enrolment in KoreaAug 31
Corporate Governance StatementAug 25

Later from Racura Oncology

Date of AGM & Closing Date for Director NominationsOct 4
Racura Presents CPACS Data at GCOS 2026Oct 6
HARNESS-1 First Cohort ClearedOct 11
Sept 2026 Quarterly Activities Report and Appendix 4COct 21
Letter to Shareholders, Notice of AGM & Proxy FormOct 21

All Racura Oncology news releases

Follow Racura Oncology into a list and get an email when it puts out news.

Follow Racura Oncology